Also, it has been shown recently that activating mutations in BRAF disrupt the hypothalamo–pituitary axis development leading to hypopituitarism, while somatic mutation of BRAF pV600E is a driver of benign tumor, papillary craniopharyngioma and is identified in corticotroph adenomas (Gualtieri et al. 2021). Here, BRAF is linked to benign neoplasm.